BIRD Symposium - When old meets new - 9 May 2020
Filip Baert, MD, PhD (AZ Delta, Roeselare, Belgium)
Dr Filip Baert is currently head of UR-Care (United Registries of Clinical Assessment and Research) at ECCO and former Chief Scientific Officer for the Governing Board of the European Crohn’s and Colitis Organization (ECCO). Filip has over 25 years of experience in clinical research and is currently Head of the Department of Gastroenterology of AZ Delta Hospital in Roeselare, Belgium, where he has developed special expertise in IBD, microscopic colitis as well as celiac disease.
Filip graduated in medicine, surgery and obstetrics from the University of Leuven in 1989. He then underwent specialization in internal medicine, gastrointestinal and liver diseases (1994), becoming a Fellow in Gastroenterology of the University of Chicago Hospitals. Next to his clinical practice he continued to be involved in translational research and acquired a PhD from the University of Leuven in 2014 on pharmacokinetics of monoclonal antibodies. He is director of the Fellowship training program in AZ Delta for the Universities of Ghent and Leuven.
He authored and co-authored > 130 peer reviewed publications and several chapters and serves as a reviewer for the key GI Journals, ECCO and UEGW. He is a Board member of BIRD (Belgian IBD Research and Development) and chairing Educom. Among his ongoing important research projects are two European registriesUR-Care (a pan European IBD electronic record/dBase) and of I-Care (Ibd CAncer and seRious infections in Europe) . Finally he serves on the editorial Board of the Journal of Crohn’s and Colitis.

Peter Bossuyt, MD (AZ Imelda, Bonheiden, Belgium)
Peter Bossuyt is a gastroenterologist at the IBD clinic in the Imelda General Hospital in Bonheiden, Belgium. He is also Co-director of the Imelda GI Clinical Research Centre in Bonheiden. Dr Bossuyt studied medicine at the Catholic University of Leuven, Belgium, and graduated in 2004 with magna cum laude. He pursued his GI fellowship in Kortrijk, Roeselare, Bonheiden and Leuven. After completing his GI fellowship, he took up a fellowship in advanced endoscopy at the Academic Medical Centre, Amsterdam. Between 2010 and 2015 he was a consulting staff member for endoscopic ultrasound at the University Hospitals of Leuven. In 2015 he started a PhD entitled, Value of endoscopic scoring and imaging for the prognosis and follow up of IBD, with Professor Séverine Vermeire as promotor. His research focuses on clinical trials in IBD and the definitions of endoscopic and imaging targets in IBD. He is a pioneer in working with e-health tools in IBD in Belgium. He is an editorial board member of the Journal of Crohn’s and Colitis, Chair of the Scientific Committee of the Belgian IBD Research and Development Group, and board member of ECCO’s Clinical Research Committee, ClinCom.

Pieter Dewint, MD, PhD (AZ Maria Middelares, Gent and UZ Antwerpen, Belgium)
Pieter Dewint (1977) studied medicine at Ghent University, where he graduated in 2002 with greatest distinction. In 2010 he completed his training in gastroenterology; and defended a doctoral thesis on aspects in basic immunology. He worked for 6 months atthe “Institut de proctologie Léopold Bellan” in Paris, refining his proctological knowledge. Afterwards, he worked for almost 5 years in Rotterdam (ErasmusMC and maasstadziekenhuis), with focus on IBD, proctology and interventional endoscopy. Since May 2015, he works both in Ghent (AZ Maria-Middelares) and Antwerp (University Hospital). He is actively involved in several national and European scientific organizations. Since 2017 he’s been member of the scientific committee of the BIRD and national representative for BIRD at ECCO. In 2018, he became assistant professor at the University Hospital Antwerp. He’s the happy father of 2 lovely daughters.

Eveline Hoefkens (AZ Imelda, Bonheiden, Belgium)
Eveline Hoefkens graduated in nursing from the Thomas More, Lier in 2015. She additionaly studied one year to specialize as an oncology nurse. While studying she was working (3 years) as a research assistant at the IBD Leuven research lab. In March 2015 she started as a pneumology/respiratory oncology nurse. Since September 2016 she works as an IBD nurse at the Imelda hospital bonheiden. From October 2018 she is president of the Belgian IBD nurses and study coordinators association (BINAstoria) and national representative for N-ECCO.

Uri Kopylov, MD (Sheba Medical Center, Ramat Gan, Israel)
Prof Kopylov graduated from Sacker Medical School of Tel Aviv University and trained in gastroenterology in Sheba Medical Center (the largest medical center in Israel). Afterwards he underwent advanced IBD training at McGill Unversity in Montreal, Canada. Since 2014 he continues working in the Department of Gastroenterology of Sheba Medical Center. He is the director of the IBD service since 2019. In addition, he is a member of ECCO Clincom and the chairman of the ECCO CLincom steering committee and is also a member of the steering committee of the Israeli IBD study group. His main fields of interest are advanced monitoring and imaging in IBD, artificial intelligence in IBD and therapeutic drug monitoring.

James Lindsay, PhD FRCP (The Royal London Hospital, London, United Kingdom)
James Lindsay is the Professor of Inflammatory Bowel Disease at Barts and the London School of Medicine and Dentistry, Queen Mary University of London and a Consultant Gastroenterologist at Barts Health NHS Trust. Along with a full multidisciplinary team he runs the adolescent and adult IBD service at The Royal London Hospital.
Professor Lindsay serves on the British Society of Gastroenterology IBD Clinical Trials Steering Group and is Chief Investigator for a series of investigator-led and commercial clinical trials in IBD.In addition, he leads a program of translational mucosal immunology research investigating leukocyte trafficking; monocyte / macrophage differentiation and the control of fibrosis in IBD.
He is the Education Officer and a member of the Governing Board of the European Crohn’s and Colitis Organisation (ECCO).Before this he served as ECCO e-learning ambassador and chair of the ECCO Education Committee. He has also chaired working groups for the ECCO consensus on the management of Crohn’s disease and ulcerative colitis. He is the British Society of Gastroenterology (BSG) national societies representative to United European Gastroenterology and is a member of the International Organisation of IBD (IOIBD)

Lieven Pouillon, MD (AZ Imelda, Bonheiden, Belgium)
Dr Lieven Pouillon received his MD in 2011 from the Katholieke Universiteit Leuven (KU Leuven) and graduated as a gastroenterologist-hepatologist in 2017. He completed a one-year IBD fellowship at CHRU Nancy in France, before starting practice at AZ Imelda Bonheiden in 2018.
Dr Pouillon currently works in the gastroenterology/hepatology department of AZ Imelda Bonheiden, where he is also part of the IBD Clinical Research Centre. Since 2019, he has been a guest lecturer at Thomas More Hogeschool, Belgium. Dr Pouillon is a reviewer for several leading gastroenterology journals including Clinical Gastroenterology and Hepatology, Alimentary Pharmacology & Therapeutics, and the Journal of Crohn’s and Colitis. He is also a member of the Young European Crohn’s and Colitis Organisation (Y-ECCO), the Flemish Association of Gastro- Enterology (VVGE) and the Belgian Inflammatory Bowel Disease Research and Development (BIRD).
To date, Dr Pouillon has authored or co-authored over 30 publications, has presented at over 10 (inter-)national congresses and has clinical trial experience as a principal and sub-investigator in over 20 (inter-)national trials. Dr Pouillon is also a member of the Noce-Bio Consensus Group, an international collaboration around the prevention and management of the nocebo effect in biosimilar-treated IBD patients.

Jean-François Rahier, MD, PhD (CHU UCL Namur, Belgium)
Jean-François Rahier was born in Belgium in 1975. He obtained his diploma of medical doctor with cum laude in 2000 from the University of Louvain (UCL) and specialized in Gastroenterology in 2007. He was first trained by Pr O Dewit in Cliniques Universitaires Saint Luc in 2005 and then by Pr JF Colombel in Lille in 2006-2007. Besides, he had a part-time research activity in 2008-2013 at the INSERM U995 laboratory of Professor Desreumaux in Lille (France) where he obtained his PhD on “lymphangiogenesis in IBD” in 2014. He is working at the University Hospital CHU UCL Namur in Belgium where his clinical activity is focused on inflammatory bowel disease (IBD) and also acted between 2014 and 2018 as consultant for phase II-III clinical trials in CHU Liège (Pr E Louis). In 2009 and 2014, he was the leading author for the European consensus on management and prevention of opportunistic infection in IBD. He has authored or co-authored more than 60 peer-reviewed manuscripts and is part of the scientific and executive committee of I-CARE. He is an active member of the Belgian IBD Group where he acts as President since 2017, of the European Crohn's and Colitis Organisation and of the GETAID (France).

Peter Verhamme, MD, PhD (UZ Leuven, Belgium)
Peter Verhamme is a Professor at the Department of Cardiovascular Sciences, Vascular Medicine and Haemostasis, at the University Hospitals Leuven, Belgium. His main clinical interests and clinical research programmes concern the prevention and treatment of venous and arterial thrombosis.
Professor Verhamme obtained his medical degree at the University of Leuven in 1997 and completed a PhD on oxidised low-density lipoprotein and atherothrombosis.
Professor Verhamme coordinates research programmes at the Centre for Molecular and Vascular Biology, University of Leuven, focusing on the development of new fibrinolytic and antithrombotic strategies, and on the interactions between inflammation, infection and coagulation. He is Chair of the Thrombosis Guidelines Group. He has authored or co-authored more than 250 papers published in various peer-reviewed journals.

Séverine Vermeire, MD, PhD (UZ Leuven, Belgium)
Séverine Vermeire obtained her MD degree at the KU Leuven in 1995 and a PhD at the same University in 2001. She trained at the Universidad Nacional de Asuncion, Paraguay, at the Wellcome Trust Centre for Human Genetics , University of Oxford UK and at the Montreal General Hospital, McGill University Canada. Since 2003 she is staff member at the Gastroenterology Department of the UZ Leuven and is appointed Professor of Medicine at the KU Leuven. Since 2016 she is Head of the Department of Chronic Diseases & Metabolism at KUL. Dr Vermeire is actively involved as principle investigator in RCTs with new therapeutic compounds and has been lead investigator on several of these programs. Her scientific work resulted in more than 600 peer-reviewed articles and focusses on the role of the microbiome and genetic susceptibility in IBD and on identifying predictive signatures of outcome and treatment response. She was awarded an Advanced ERC Grant from the EU in 2016. Dr Vermeire is Past-President of the Belgian IBD Research & Development (BIRD) Group and of the European Crohn’s and Colitis Organisation (ECCO).